Article Contents ::
- 1 The Brand Name NEXTOP Has Generic Salt :: Topiramate
- 2 NEXTOP Is From Company Torrent Priced :: Rs. 59.3
- 3 NEXTOP have Topiramate is comes under Sub class Anti Epileptics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name NEXTOP Has Generic Salt :: Topiramate
NEXTOP Is From Company Torrent Priced :: Rs. 59.3
NEXTOP have Topiramate is comes under Sub class Anti Epileptics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Epilepsy, Migraine prophylaxis, Seizures associated w/ Lennox-gastaut syndrome
Drug Dose ::
Adult: PO Adjunct in seizures associated w/ Lennox-gastaut syndrome Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 200-400 mg/day in two divided doses. Max: 800 mg/day. Epilepsy Monotherapy: Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 100-400 mg/day in two divided doses. Max: 400 mg/day. Adjunct: Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 200-400 mg/day. Max: 800 mg/day. Migraine prophylaxis >16 yr: Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 50-100 mg/day in 2 divided doses. Child: (Age 2 – 16 Years): Partial Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome – The recommended total daily dose of Topiramate as adjunctive therapy is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1 or 2 weeks intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Migraine: The recommended total daily dose of Topiramate as treatment for prophylaxis of migraine headache is 100 mg/day administered in two divided doses.
Contraindicated in persons showing hypersensitivity to any component of this preparation.
Drug Precautions ::
Renal or hepatic impairment, pregnancy, lactation. May impair ability to drive or operate machinery. Maintain adequate hydration to reduce the risk of renal calculi especially in predisposed patients. Measure serum bicarbonate at baseline and periodically during treatment. Avoid abrupt withdrawal; decrease dose by 100 mg daily at wkly intervals. Seek immediate medical attention if blurred vision or eye pain. Monitor closely for decreased sweating and increased body temperature, especially in hot weather. Ensure proper hydration before and during activities or exposure to warm temperatures.
Drug Side Effects ::
Confusion, dizziness, drowsiness, generalised slowing of mental and physical activity, difficulty with concentrations, ataxia, paresthesia, anorexia, weight loss, abnormal vision, metabolic acidosis, mood or mental changes, behavioural disturbances, depression, fatigue, agitation, nervousness, anxiety, oligohidrosis, hyperthermia and hyperammonaemic encephalopathy.
Pregnancy category ::
Drug Mode of Action ::
Topiramate is a sulfamate-substituted monosaccharide with precise mechanism of action unknown. It may be due to various mechanisms e.g. blocking of voltage-dependent sodium channels; augmenting the activity of ?-aminobutyric acid (GABA) at GABA-A receptor; antagonising AMPA/kainate glutamate receptors; inhibiting carbonic anhydrase.
Drug Interactions ::
Coadmin with antiepileptic drugs e.g. phenytoin, carbamazepine, phenobarbital decreases plasma concentration of topiramate. Possible increase in phenytoin levels. Increased risk of renal stone formation with carbonic anhydrase inhibitors e.g. acetazolamide. Increased risk of CNS depression with CNS depressants and alcohol. Increased risk of hyperammonaemia and encephalopathy with valproic acid. Increased risk of contraceptive failure in women taking combined oral contraceptives.